Role of bisphosphonates in non-metastatic prostate cancer

Fred Saad¹

Affiliations

Comment

Fred Saad. Lancet Oncol. 2014 Sep.

. 2014 Sep;15(10):1041-2.

doi: 10.1016/S1470-2045(14)70363-8. Epub 2014 Aug 14.

Fred Saad¹

¹ Departments of Surgery and Urology, University of Montreal Health Center, Montréal, Quebec, Canada H2X 0A9.

No abstract available

Comment on

Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): an open-label, randomised, phase 3 factorial trial.
Denham JW, Joseph D, Lamb DS, Spry NA, Duchesne G, Matthews J, Atkinson C, Tai KH, Christie D, Kenny L, Turner S, Gogna NK, Diamond T, Delahunt B, Oldmeadow C, Attia J, Steigler A. Denham JW, et al. Lancet Oncol. 2014 Sep;15(10):1076-89. doi: 10.1016/S1470-2045(14)70328-6. Epub 2014 Aug 14. Lancet Oncol. 2014. PMID: 25130995 Clinical Trial.